INTRODUCTION AND OBJECTIVES: mpMRI offers the possibility to locate cancer in 3-Dimensions and aid surgical planning. We investigated the margin needed around an mpMRI lesion for complete disease control in a prospectively enrolled biopsy naïve population who underwent mpMRI followed by Transperineal Prostate Mapping with biopsies taken every 5mm(5TPM).
INTRODUCTION AND OBJECTIVES: mpMRI offers the possibility to locate cancer in 3-Dimensions and aid surgical planning. We investigated the margin needed around an mpMRI lesion for complete disease control in a prospectively enrolled biopsy naïve population who underwent mpMRI followed by Transperineal Prostate Mapping with biopsies taken every 5mm(5TPM).
METHODS: 94 patients included in this analysis were part of the pilot phase of Prostate MRI Imaging Study (NCT01292291) investigating accuracy of mpMRI against standard of care with TPM as a reference test. All patients were biopsy-naïve with a PSA below 15ng/ ml. All patients underwent 1.5T mpMRI with standardized protocol (T2W, Diffusion, DCE), blinded reported using Likert scoring. Each core was separately labelled and oriented in space. Each prostate and MRI lesion was contoured on T2W-imaging, blinded to pathology. A 3D digital map of the TPM was reconstructed using an in-house software. Correlation between mpMRI and biopsy findings was automatically carried out using a platform generating the registration based on landmarks. We report the margin 'M' around the MRI lesion as the maximum distance within a set of negative biopsy location surrounding the MRI lesion. Results are also stratified by MRI score, Gleason Score, lesion eligibility to focal therapy and significance.
RESULTS: 41 patients (median PSA 6.5ng/ml, median age 62) were found to harbour cancer at 5TPM in this cohort, yielding 75 MRI lesions that corresponded to cancer at 5TPM. The median number of MRI lesions per patient was 1.5. As a control of registration, correlation between MRI volume and TPM volume was ?¼0.92 (p<0.001). Lesion characteristics are summarized in Table 1 . The mean margin (enclosing a perimeter of negative cores) for MRI lesions corresponding the cancer at 5TPM was 7.0 mm (SD 4.6mm). For lesion eligible for focal therapy (n¼ 35), the mean margin was 7.3 (SD 4.3mm). The mean Gleason score of biopsy core outside the MRI lesion was 6.7 (+/-0.5).
CONCLUSIONS: Our study is the first to report a margin around a mpMRI lesion when based on prostates that have not been removed using surgery and evaluated against a very accurate 3-dimensional 5mm mapping biopsy. These findings have implications for focal therapy and nerve-sparing surgery. is the most common imaging modality used for detecting residual cancer following Partial Gland Ablation (PGA) for Prostate Cancer. The aim of this study was to assess the diagnostic accuracy of mp-MRI to detect residual cancer in the ablated area following PGA and to assess whether a biopsy of the ablated area may be avoided based on MRI.
Source of
METHODS: Prospectively maintained institutional database was queried to identify 65 patients with primary PGA from May 2010 to February 2016 and had a postoperative MRI and a control biopsy within 18 months after the procedure. All the MRIs were reviewed by a single radiologist blinded to the biopsy results and visible abnormalities in the ablated area were scored based on a 5-point Likert scale and PIRADS V2. Univariate generalized estimating equation regression with an exchangeable correlation structure to account for within patient correlation was used to test the association between a high MRI score (Likert or PIRADS score ¼3) and any-(Gleason ¼6) and high-grade (Gleason ¼7) disease detected on biopsy of the ablated area.
RESULTS: After exclusions, we identified 38 post-PGA MRI and biopsy pairs with 6 patients having 2 MRI/biopsy combinations. Any-grade disease was detected on 15 biopsies (39%; 95% CI 24%, 57%) and high-grade on 2 biopsies (5.3%; 95% CI 0.6%, 18%). Patient with MRI lesion of Likert and PIRADS score ¼3 in the ablated area were 8 (21%) and 7 (18%) respectively. Both the 2 instances of high-grade disease detected on biopsy occurred among the 8 MRIs with a Likert score ¼3 (25%; 95% CI 3.2%, 65%) and 7 MRIs with a PIRADS score ¼3. No high-grade disease was detected among participants with a Likert or PIRADS score <3, the upper bound of a 97.5% exact confidence interval was 11.6% and 11.2% based on Likert score (n¼30) and PIRADS Score (n¼31) respectively. One patient had a PIRADS score of 5 and had a Gleason 6 disease detected on biopsy. We did not find sufficient evidence to suggest an association between a PIRADS score and any-grade disease (p ¼ 0.6) nor between Likert score and anygrade disease (p ¼ 0.9), the association was not estimable as we had no participants with high-grade disease with an MRI score less than 3.
CONCLUSIONS: This preliminary study was unable to identify an association between MRI scores and presence of prostate cancer in the treated area following PGA therapy. Men with MRI scores of <3 should not be precluded from biopsy given that it is plausible that the rate of high-grade disease is meaningfully high. Daniel Halpern*, Michael Kongnyuy, Kaitlin Kosinski, Jeffrey Schiff, Anthony Corcoran, Aaron Katz, Mineola, NY INTRODUCTION AND OBJECTIVES: Biochemical recurrence (BCR) after primary focal cryosurgery (PFC) is determined using criteria (Phoenix, ASTRO) designed for post radiation patients. These criteria are limiting, hence the need for PFC-specific BCR criteria. We report on MRI characteristics of post-PFC patients with suspected BCR.
Source of Funding: None
METHODS: We retrospectively reviewed patients who underwent PFC. Prostate specific antigen (PSA) nadir was determined using 2 PSA values. BCR was determined using Phoenix criteria (nadir + 2 Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e935 ng/ml). Pre-and post-PFC multiparametric MRIs (mpMRI) were obtained and biopsies were performed. RESULTS: Ninety (51.1%) of 176 patients who underwent PFC had more than 2 post-PFC PSAs. Of those who experienced BCR (41.1%) (median time to BCR 19.9 months), 27 (73.0%) underwent mpMRI (Table 1) . Seventeen (45.9%) mpMRIs were found with a suspicious lesion, 58.8% were ipsilateral compared to pre-PFC mpMRI and location of pre-PFC positive cores. 35.3% of lesions were located in the central gland of the prostate. Five of 11 patients with positive post-PFC MRI were positive on biopsy. Seven of 17 patients with positive MRIs received definitive treatment.
CONCLUSIONS: Post-PFC MRI at suspected BCR may help identify a significant number of patients failing PFC.
Source of Funding: Department of Urology, Winthrop University Hospital

MP70-05 DEFINING THE INDEX LESION FOR SALVAGE PARTIAL GLAND ABLATION AFTER RADIATION THERAPY FOR LOCALIZED PROSTATE CANCER
Arjun Sivaraman*, Toshikazu Takeda, Hebert Alberto Vargas, Samson Fine, James Eastham, Behfar Ehdaie, New York, NY INTRODUCTION AND OBJECTIVES: Partial gland ablation (PGA) is a promising treatment for selected patients with recurrent localized prostate cancer after radiation therapy. Our objective was to evaluate the impact of MRI and systematic biopsy characteristics to identify the index lesion for salvage partial gland ablation using tumor maps from whole mount slides of salvage radical prostatectomy (sRP) specimen.
METHODS: We identified 225 patients who underwent sRP between 2000 and 2014 and a tumor map was created from wholemount slides in 77 patients. Among these patients, we selected men with a priori pre-treatment criteria considered eligible for PGA, including, biopsy proven unilateral disease concordant with a region of interest (ROI) on MRI, and excluding men with imaging suspicious for extra-capsular extension (ECE), seminal vesicle Invasion (SVI) or lymph node involvement (LNI). We describe the correlation between pre-treatment clinical characteristics and final radical prostatectomy whole mount specimen to select men eligible for PGA defined as hemi-gland ablation.
RESULTS: Among 77 patients with a tumor map of entirelysubmitted and whole-mounted specimens, 15 patients were determined to be eligible for partial gland ablation based on pre-treatment clinical characteristics. The mean age was 60 years and median time from primary RT was 48 months. The median (IQR) tumor volume of the index lesion was 0.3 (0.4) cc. The location of the index lesion was determined to be the apex, mid-gland and base in 77%, 100% and 15% of patients, respectively. The median distance of the index tumor to the urethra was 0.5 (0.2) cm. The index tumor was confined to one lobe and concordant to the biopsy pathology and MRI data in all 15 patients (100%). There was no ECE, LNI or SVI identified in the sRP specimens. To account for those patients who did not have a tumor map of the whole-mount specimen, a sensitivity analysis was performed and determined that the clinical characteristics of the 77 patients with tumor maps were comparable to the entire 225 sRP cohort.
CONCLUSIONS: Clinical characteristics guided by biopsy findings and MRI data can be used to select men for PGA with recurrent localized prostate cancer after radiation therapy. Based on tumor maps from whole-mount slides of sRP specimen, we propose that salvage hemi-gland ablation including periurethral tissue is feasible in select patients with biopsy proven unilateral disease concordant with MRI data.
Source of Funding: None
MP70-06 PREDICTING ONCOLOGICAL CONTROL FOLLOWING FOCAL ABLATION(FA) OF PROSTATE CANCER(PCA)
Alexander Kenigsberg*, Elton Llukani, Fang-Ming Deng, Jonathan Melamed, Herbert Lepor, New York, NY INTRODUCTION AND OBJECTIVES: There is increasing interest in FA for select cases of PCa. The objective of this study is to provide insights into oncological control following FA.
METHODS: 59 men who underwent radical prostatectomy (RP) between 2012 and 2016 fulfilled criteria for FA: a single MRI lesion (MRI-L) concordant with biopsy Gleason score (GS) <8, no gross extra-prostatic extension on MRI, no GS>6 or GS 6 core length>5mm contralateral to the single MRI-L on 12 core systematic biopsy. All RP surgical specimens were sectioned transversely every 3mm. The greatest linear dimension, GS and extent of Gleason pattern (GP) 4 of all tumor foci were recorded and related to scale on corresponding 3 mm transverse slice prostate maps. Clinically significant secondary cancers (CSSC) were defined as GS 6>5mm or any GP 4 not detected by mpMRI. The location of these CSSC relative to the MRI-L and the distance from the peripheries of the CSSC and the MRI-L were recorded and used to predict oncological control following theoretic ablation templates (TAT) of MRI-L + 10mm margin or hemi-ablation.
RESULTS: Overall, 29 (49%) of the prostates had at least one CSSC. Of the total 50 CSSC, 15 (30%), 34 (68%) and 1 (2%) were ipsilateral, contralateral and midline to the MRI-L. Of the 50 CSSC, 30 (60%), 16 (32%), and 4(8%) were GS 6 > 5mm, GS 3 +4, and GS >3 + 4 respectively. The median greatest linear dimensions (MGLD) of the GS 6, GS 3 + 4, and GS > 3 + 4 PCa were 7.5mm, 5mm, and 2mm, respectively. The MGLD of the ipsilateral vs contralateral CSSC were not significantly different. Of the 20 CSSC with any GP 4, 10 (50%) exhibited a MGLD < 5 mm. The median GP 4 length in missed CSSCs was 0.8mm (range 0.1-2.4mm). A MRI-L + 10mm margin vs hemiablation would leave residual GP4 CSSC in 14 (23.7%) vs. 10 (16.9%) cases (p¼.36), respectively CONCLUSIONS: Approximately half of candidates meeting our criteria for FA have CSSC. Since 50% of these CSSC were <5mm, many were not detected by MRI. In addition, the median GP 4 length was only 0.8mm, suggesting that many of these CSSC were of equivocal biological significance. Of the CSSC, 68% were contralateral to MRI-L suggesting similar oncological limitations of TAT of MRI-L + 10mm margin and hemi-ablation. Our study provides compelling evidence that all men undergoing FA require active surveillance for disease both within and outside the AT.
